{"id":39396,"date":"2016-10-25T14:21:40","date_gmt":"2016-10-25T18:21:40","guid":{"rendered":"http:\/\/www.bumc.bu.edu\/busm\/?p=39396"},"modified":"2016-10-25T14:21:40","modified_gmt":"2016-10-25T18:21:40","slug":"study-determines-efficacy-of-two-drugs-to-treat-a-form-of-leukemia","status":"publish","type":"post","link":"https:\/\/www.bumc.bu.edu\/camed\/2016\/10\/25\/study-determines-efficacy-of-two-drugs-to-treat-a-form-of-leukemia\/","title":{"rendered":"Study Determines Efficacy of Two Drugs to Treat a Form of Leukemia"},"content":{"rendered":"<p>Researchers have determined that two Phase 1 drugs (CX-4945 and JQ1) can work together to efficiently kill T-cell acute lymphoblastic leukemia cells while having minimal impact on normal blood cells.<\/p>\n<p><img loading=\"lazy\" src=\"\/camed\/files\/2016\/10\/COM-Acute_leukemia-ALL-e1477419664780.jpg\" alt=\"COM Acute_leukemia-ALL\" class=\"alignright size-full wp-image-39495\" width=\"200\" height=\"228\" \/>Although both drugs were previously tested as single agents in clinical trials to treat cancers, the success of the combined actions on cancer cells was previously unknown until now. The findings appear in the journal <em>Haematologica<\/em>.<\/p>\n<p>Acute lymphoblastic leukemia, also known as acute lymphocytic leukemia or acute lymphoid leukemia, is a form of cancer of the white blood cells, characterized by the overproduction and accumulation of cancerous, immature white blood cells, known as lymphoblasts. Despite treatment improvement, T-cell leukemia remains fatal in 20 percent of pediatric and 50 percent of adult patients. Both CX-4945 and JQ1 are in clinical trials now as single agents to treat solid and hematological cancers.<\/p>\n<figure id=\"attachment_4474\" aria-describedby=\"caption-attachment-4474\" style=\"width: 138px\" class=\"wp-caption alignleft\"><img loading=\"lazy\" src=\"\/camed\/files\/2015\/06\/Hui-Feng.jpg\" alt=\"Hui Feng\" class=\"size-full wp-image-4474\" width=\"128\" height=\"150\" \/><figcaption id=\"caption-attachment-4474\" class=\"wp-caption-text\">Hui Feng<\/figcaption><\/figure>\n<p>\u201cPrevious studies provided us a rationale to test the combination of CX-4945 and JQ1 on refractory\/relapsed T-cell leukemia,\u201d said corresponding author Hui Feng, MD, PhD, assistant professor of pharmacology &amp; experimental therapeutics. \u201cOur findings suggest that the combination treatment of CX-4945 and JQ1 could be an effective strategy to target refractory\/relapsed T-cell leukemia,\u201d she added.<\/p>\n<p>According to the researchers the efficacy of using a combination of JQ1 and CX-4945 in treating other cancers should also be investigated.<\/p>\n<p>This research was led by Haiwei Lian, a co-trained PhD candidate in Feng\u2019s laboratory and Dr. Hui Fu\u2019s laboratory at Wuhan University (China), through a close collaboration with Dr. Esther Landesman and the late Dr. David Seldin at BUSM.<\/p>\n<p>Funding for this study was provided by Boston University, the National Institutes of Health, the Leukemia Research Foundation, the St. Baldrick Foundation, the Rally Foundation and the Alex Lemonade Stand Foundation.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>According to corresponding author Hui Feng, MD, PhD, assistant professor of Pharmacology &#038; Experimental Therapeutics, the combination treatment could be an effective strategy to target refractory\/relapsed T-cell leukemia. <\/p>\n","protected":false},"author":903,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[91,90],"tags":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/posts\/39396"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/users\/903"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/comments?post=39396"}],"version-history":[{"count":2,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/posts\/39396\/revisions"}],"predecessor-version":[{"id":39496,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/posts\/39396\/revisions\/39496"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/media?parent=39396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/categories?post=39396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/tags?post=39396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}